Cystatin C as a Candidate Biomarker of Cardiovascular Outcomes: Too Near, but too Far from Reality by Luiz Sérgio F. de Carvalho, Thiago Quinaglia AC Silva, Otávio Rizzi Coelho-Filho

Get full text

GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data by Andrei C. Sposito, Otávio Berwanger, Luiz Sérgio F. de Carvalho, José Francisco Kerr Saraiva

Get full text

Comparative effectiveness and cost-effectiveness of cardioprotective glucose-lowering therapies for type 2 diabetes in Brazil: a Bayesian network model by Ana Claudia Cavalcante Nogueira, Joaquim Barreto, Filipe A. Moura, Beatriz Luchiari, Abrão Abuhab, Isabella Bonilha, Wilson Nadruz, J. Michael Gaziano, Thomas Gaziano, Luiz Sergio F. de Carvalho, Andrei C. Sposito, on behalf of the Brazilian Heart Study Group

Get full text

O Impacto Clínico e Econômico do Atraso na Terapia de Reperfusão: Evidências do Mundo Real by Silvio Gioppatto, Paulo Sousa Prado, Mariana Araújo Lima Elias, Verônica Homem de Carvalho, Caio Resende da Costa Paiva, Gustavo de Almeida Alexim, Ricardo Torres Bispo Reis, Ana Claudia Cavalcante Nogueira, Alexandre Anderson de Sousa Munhoz Soares, Wilson Nadruz, Luiz Sergio F. de Carvalho, Andrei C. Sposito

Get full text

Evolocumab on top of empagliflozin improves endothelial function of individuals with diabetes: randomized active-controlled trial by Andrei C. Sposito, Ikaro Breder, Joaquim Barreto, Jessica Breder, Isabella Bonilha, Marcus Lima, Alessandra Oliveira, Vaneza Wolf, Beatriz Luchiari, Helison R. do Carmo, Daniel Munhoz, Daniela Oliveira, Otavio R. Coelho-Filho, Otavio R. Coelho, Jose Roberto Matos-Souza, Filipe A. Moura, Luiz Sergio F. de Carvalho, Wilson Nadruz, Thiago Quinaglia, Sheila T. Kimura-Medorima, the EXCEED-BHS3 Group

Get full text